Increasing Dose of Autologous Bone Marrow Mononuclear Cells Transplantation Is Related to Stroke Outcome: Results from a Pooled Analysis of Two Clinical Trials
Open Access
- 1 January 2016
- journal article
- research article
- Published by Wiley in Stem Cells International
- Vol. 2016 (1) , 8657173
Abstract
Background and Purpose. BM‐MNC transplantation improves recovery in experimental models of ischemic stroke. Clinical trials are ongoing to test efficacy in stroke patients. However, whether cell dose is related to outcomes is not known. Methods. We performed a pooling data analysis of two pilot clinical trials with autologous BM‐MNCs transplantation in ischemic stroke patients. Cell dose and route were analyzed to evaluate their relation to good outcome (m‐Rankin scale [mRS] score 0–2) at 6 months. Results. Twenty‐two patients were included. A median of 153 × 106 (±121 × 106) BM‐MNCs was injected. Intra‐arterial route was used in 77.3% of cases. A higher number of cells injected were associated with better outcomes at 180 days (390 × 106 [320–422] BM‐MNCs injected in those patients with mRS of 0–2 at 6 months versus 130 × 106 [89–210] in those patients with mRS 3–6, p = 0.015). In the intra‐arterially treated patients, a strong correlation between dose of cells and disability was found (r = −0.63, p = 0.006). A cut point of 310 × 106 injected cells predicted good outcome with 80% sensitivity and 88.2% specificity. Conclusions. Similar to preclinical studies, a higher dose of autologous BM‐MNC was related to better outcome in stroke patients, especially when more than 310 × 106 cells are injected. Further interventional studies are warranted to confirm these data.Keywords
Funding Information
- Fundación Mutua Madrileña
- Instituto de Salud Carlos III (PI15/01197)
This publication has 29 references indexed in Scilit:
- Intravenous Autologous Bone Marrow Mononuclear Cell Transplantation for Stroke: Phase1/2a Clinical Trial in a Homogeneous Group of Stroke PatientsStem Cells and Development, 2015
- Intra-Arterial Bone Marrow Mononuclear Cell Transplantation Correlates with GM-CSF, PDGF-BB, and MMP-2 Serum Levels in Stroke Patients: Results from a Clinical TrialCell Transplantation, 2014
- Cell TherapiesStroke, 2013
- Biodistribution of Bone Marrow Mononuclear Cells After Intra-Arterial or Intravenous Transplantation in Subacute Stroke PatientsRegenerative Medicine, 2013
- Intra-Arterial Bone Marrow Mononuclear Cells in Ischemic StrokeStroke, 2012
- Intra-Arterial Infusion of Autologous Bone Marrow Mononuclear Cells in Patients with Moderate to Severe Middle Cerebral Artery Acute Ischemic StrokeCell Transplantation, 2012
- Intravenous autologous bone marrow mononuclear cells for ischemic strokeAnnals of Neurology, 2011
- Safety of Autologous Bone Marrow Mononuclear Cell Transplantation in Patients with Nonacute Ischemic StrokeRegenerative Medicine, 2010
- Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinicThe Lancet Neurology, 2009
- Interobserver agreement for the assessment of handicap in stroke patients.Stroke, 1988